Q2 2003 RESULTS PRESENTATION - 31 July 2003
Basingstoke, UK - 15 July 2003 - Shire Pharmaceuticals Group plc (LSE: SHP,
NASDAQ: SHPGY; TSX: SHQ) will announce second quarter 2003 earnings on Thursday,
31 July 2003.
Results announcement time: 12:00 BST / 07:00 ET
Conference call time: 14:00 BST / 09:00 ET
Live conference call:
The details of the live conference call are as follows:
UK dial in + 44 1452 542 304
US / Canada dial in 1866 389 9780
Password Shire Pharmaceuticals
Live audio webcast:
There will also be a live audio webcast available, accessible through
www.shire.com in the investor relations section. A slide presentation to
accompany the call will also be available on the Shire website.
Replay:
A replay of the presentation will be available for 2 weeks. Details are
as follows:
----------------------------------------- ------------------------------------
UK International no: + 44 (0)1452 55 00 00
----------------------------------------- ------------------------------------
UK PIN (access) no: 321825#
----------------------------------------- ------------------------------------
US no: 1866 276 1167
----------------------------------------- ------------------------------------
US PIN (access) no: 321825#
----------------------------------------- ------------------------------------
Webcast Replay www.shire.com, in the investor
relations section
If you have any problems accessing this, please contact: Souheil Salah on: +44
(0) 1256 894 160
End
For further information please contact:
Global Investor Relations
Clea Rosenfeld +44 (0)1256 894 160
North America Investor Relations
Gordon Ngan +44 (0)1256 894 160
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a rapidly growing international
emerging pharmaceutical company with a strategic focus on four therapeutic areas
- - central nervous system disorders (CNS), gastrointestinal (GI), oncology, and
anti-infectives. Shire also has three platform technologies: advanced drug
delivery, lead optimisation for small molecules and Biologics. Shire's core
strategy is based on research and development combined with in-licensing and a
focus on key pharmaceutical markets.
For further information on Shire, please visit the Company's website:
www.shire.com
THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995. Statements included herein that are not historical facts, are
forward-looking statements. Such forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event such
risks or uncertainties materialise, Shire's results could be materially
affected. The risks and uncertainties include, but are not limited to, risks
associated with the inherent uncertainty of pharmaceutical research, product
development, manufacturing and commercialisation, the impact of competitive
products, including, but not limited to, the impact on Shire's Attention Deficit
Hyperactivity Disorder (ADHD) franchise, patents, including but not limited to,
legal challenges relating to Shire's ADHD franchise, government regulation and
approval, including but not limited to the expected product approval date of
lanthanum carbonate (FOSRENOL(R)) and METHYPATCH (R) , and other risks and
uncertainties detailed from time to time in our filings, including the Annual
Report filed on Form 10-K by Shire with the Securities and Exchange Commission.